TRIMTECH Therapeutics develops CNS-penetrant TRIMTAC degrader molecules that harness TRIM21 to selectively remove pathogenic protein aggregates while preserving functional monomers for neurodegenerative and inflammatory disorders.
Part of: Boston tech scene from Fundable